Olivia Wen1, Samuel C Wolff2, Wayne Stallaert3

  • 1Department of Biology, University of North Carolina at Chapel Hill, NC, United States.

概括

CDK4/6抑制剂在ER+/HER2-乳腺癌中表现有前途,但耐药性很常见. 新的计算方法揭示了细胞周期的变化和潜在的抵抗机制,有助于精确医学的发展.